All In Biotech

Drug Trial Radar · NCT00000796

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

525

Actual

Start

Not stated

Primary completion

Not stated

Study completion Oct 1998

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.

Conditions

  • HIV Infections
  • Tuberculosis

Interventions

  • CycloserineDrug

  • EthionamideDrug

  • Capreomycin sulfateDrug

  • Aminosalicylic acidDrug

  • Streptomycin sulfateDrug

  • Ethambutol hydrochlorideDrug

  • Amikacin sulfateDrug

  • IsoniazidDrug

  • PyrazinamideDrug

  • Pyridoxine hydrochlorideDrug

  • LevofloxacinDrug

  • RifampinDrug

  • ClofazimineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cook County Hosp

    Chicago, Illinois

  • Henry Ford Hosp

    Detroit, Michigan

  • Interfaith Med Ctr

    Brooklyn, New York

  • SUNY / Health Sciences Ctr at Brooklyn

    Brooklyn, New York

  • Beth Israel Med Ctr

    New York, New York

  • Clinical Directors Network of Region II

    New York, New York

  • Bellevue Hosp / New York Univ Med Ctr

    New York, New York

  • Saint Clare's Hosp and Health Ctr

    New York, New York

  • Cornell Univ Med Ctr

    New York, New York

  • Mount Sinai Med Ctr

    New York, New York

  • Columbia Presbyterian Med Ctr

    New York, New York

  • Harlem AIDS Treatment Group / Harlem Hosp Ctr

    New York, New York

  • Bronx Lebanon Hosp Ctr

    The Bronx, New York

  • Bronx Municipal Hosp Ctr/Jacobi Med Ctr

    The Bronx, New York

  • Comprehensive Health Care Ctr / Bronx Municipal Hosp

    The Bronx, New York

  • Montefiore Drug Treatment Ctr / Bronx Municipal Hosp

    The Bronx, New York

  • Montefiore Family Health Ctr / Bronx Municipal Hosp

    The Bronx, New York

  • Samaritan Village Inc / Bronx Municipal Hosp

    The Bronx, New York

  • Jack Weiler Hosp / Bronx Municipal Hosp

    The Bronx, New York

  • Montefiore Med Ctr / Bronx Municipal Hosp

    The Bronx, New York

  • North Central Bronx Hosp / Bronx Municipal Hosp

    The Bronx, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.